Alogliptin, sold under the brand names Nesina and Vipidia,[2][3] is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class.

[4] Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity.

[9] Adverse events include hypoglycemia,[10][11][12] pruritis (itching),[3] nasopharyngitis, headache, and upper respiratory tract infection.

[15][better source needed] In April 2016, the U.S. Food and Drug Administration (FDA) added a warning about increased risk of heart failure.

[16] The company also filed a Marketing Authorization Application elsewhere outside the United States, which was withdrawn in June 2009 needing more data.